[Skip to Content]
[Skip to Content Landing]
Views 315
Citations 0
Comment & Response
May 2, 2019

Aspirin Use and the Risk of Cancer—In Reply

Author Affiliations
  • 1Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston
  • 4Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City
  • 5Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 6Broad Institute, Boston, Massachusetts
  • 7Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston Massachusetts
JAMA Oncol. 2019;5(6):913. doi:10.1001/jamaoncol.2019.0633

In Reply We thank Skelin and colleagues for their interest in our prospective population-based studies of aspirin use and the risk of incident hepatocellular carcinoma (HCC)1 and ovarian cancer.2 As Skelin asserts, our site-specific findings should be examined in conjunction with research on total cancer incidence. Our prior study of these same cohorts found that regular (≥325 mg, ≥2 times per week) vs nonregular aspirin use was associated with a hazard ratio of 0.97 (95% CI, 0.94-0.99) for overall cancer.3 A meta-analysis of 34 randomized clinical trials (RCTs) of aspirin and total cancer death reported similar results,4 so we believe population-based research of aspirin and site-specific cancer incidence remains valid and important.

×